Your browser does not support the video tag.
Skip to content
home button
  • Resources
    • By Topic
      • Access to Clinical Trials
      • Artificial Intelligence
      • Clinical Trials Landscape
      • Data Collecting + Reporting
      • Ensuring Quality
      • Innovative Trials
      • Patient Engagement
      • Recruitment
      • Regulatory Submissions + Approvals
      • Safety
      • Site Planning
    • By Trial Stage
      • Study Design
        • Innovative Trials
        • Patient Group Engagement
        • Recruitment
      • Study Operations
        • Data Collecting
        • Regulatory Submissions + Approvals
        • Site Planning
  • Case Studies
  • About CTTI
  • Newsroom
  • Membership
  • Annual Report
connect with us
Signup for our Newsletter
  • About CTTI
  • Newsroom
  • Membership
  • Annual Report
Search

CTTI

Clinical Trials Transformation Initiative

Case Study: Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer

Posted on June 8, 2005February 10, 2025 by Hannah Faulkner

Case Study: Trial of NES-822 plus AMO-1022 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer

This entry was posted in Ensuring Quality, Quality By Design, Quality by Design, Resources, Study Design. Bookmark the permalink.

Post navigation

← Case Study: A prospective, multicenter, single-arm, clinical cohort study
Case Study: A Study to Evaluate the Efficacy and Safety of XXXX compared to YYYY in the Treatment of Patients with Acute Episode of Schizophrenia (Hospitalized) →

DISCLAIMER: CTTI encourages the use of all materials listed on this site in the pursuit of improving the clinical trials enterprise. Our recommendations, tools, meeting summaries, and more are available to the public for free. We do ask that you acknowledge the source whenever using or referencing CTTI materials. Read our Citation Policy. 

  • About
  • Newsroom
  • Membership
  • Case Studies
  • Contact Us
  • Access to Clinical Trials
  • Artificial Intelligence
  • Clinical Trials Landscape
  • Data Collecting + Reporting
  • Ensuring Quality
  • Innovative Trials
  • Informed Consent
  • Patient Group Engagement
  • Real-World Data
  • Recruitment
  • Regulatory Submissions + Approvals
  • Safety + Protection
  • Site Planning
Sign up for our Newsletter
Log in

© Clinical Trials Transformation Initiative © 2026

terms of use

privacy statement

WordPress is a content management system and should not be used to upload any PHI as it is not an environment for which we exercise oversight, meaning you the author are responsible for the content you post. Please use this system accordingly.